What is Celularity?
Celularity Inc. operates as a sophisticated biopharmaceutical entity dedicated to the development of off-the-shelf cell therapy product candidates. The company utilizes its unique platform to address aging-related and degenerative diseases, with a primary focus on mesenchymal-like adherent stromal cells. Its operational framework is divided into three distinct segments: Cell Therapy, Degenerative Disease, and BioBanking. Through programs such as PDA-001 and PDA-002, the firm is actively exploring treatments for autoimmune disorders like Crohn's disease and facioscapulohumeral muscular dystrophy. By maintaining a robust portfolio of intellectual property and clinical assets, Celularity remains a critical innovator in the pursuit of precision medicine and advanced therapeutic interventions.
How much funding has Celularity raised?
Celularity has raised a total of $285.1M across 6 funding rounds:
Unspecified
$250M
Multiple Rounds
$21.8M
Other Financing Round
$13.3M
Unspecified (2018): $250M with participation from Heritage Group, Sorrento Therapeutics, Celgene, United Therapeutics, Genting Berhad, Human Longevity, the Dreyfus Family Office, and Section 32
Stock/Share Issuance (2025): $1M, investors not publicly disclosed
Debt (2025): $6.8M, investors not publicly disclosed
Stock/Share Issuance (2025): $2M, investors not publicly disclosed
Debt (2025): $12M, investors not publicly disclosed
Other Financing Round (2026): $13.3M with participation from NEXGEL
Key Investors in Celularity
Heritage Group
Heritage Group provides a comprehensive suite of services designed to integrate with commercial real estate platforms, focusing on investment management and property optimization.
Sorrento Therapeutics
Sorrento Therapeutics is a clinical-stage, antibody-centric biopharmaceutical company headquartered in San Diego, specializing in the development of novel cancer therapies.
United Therapeutics
United Therapeutics is a biotechnology firm focused on the discovery and commercialization of innovative therapies for patients living with chronic, rare, and life-threatening diseases.
What's next for Celularity?
With the recent influx of capital, Celularity is well-positioned to accelerate its clinical development milestones and expand its manufacturing capabilities. The strategic focus will likely shift toward scaling the production of its allogeneic cell therapy candidates to meet the demands of upcoming late-stage trials. Furthermore, the company is expected to leverage its BioBanking segment to enhance its research infrastructure, potentially opening new avenues for commercial partnerships and global market penetration. As the firm navigates the complexities of the regulatory landscape, this financial backing provides the necessary runway to transition from clinical-stage research to broader therapeutic application, ultimately aiming to redefine the standard of care for patients suffering from chronic and degenerative illnesses.
See full Celularity company page
